Unió Europea - italià - EMA (European Medicines Agency)

glaxosmithkline trading services - mepolizumab - asma - farmaci per le malattie respiratorie ostruttive, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.

Unió Europea - italià - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19f - pneumococcal infections; immunization - vaccini - immunizzazione attiva contro la malattia invasiva e l'otite media acuta causata da streptococcus pneumoniae in neonati e bambini da sei settimane fino a cinque anni. vedi sezioni 4. 4 e 5. 1 nelle informazioni sul prodotto per informazioni sulla protezione da sierotipi di pneumococco specifici. l'uso di synflorix deve essere determinato sulla base di raccomandazioni ufficiali, tenendo in considerazione l'impatto della malattia invasiva in diversi gruppi di età, così come la variabilità del sierotipo epidemiologia in diverse aree geografiche.

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - betamethasonum - crema - betamethasonum 1 mg ut betamethasoni valeras, macrogoli aether cetostearylicus, alcohol cetylicus et stearylicus 72 mg, vaselinum album, paraffinum liquidum, natrii dihydrogenophosphas dihydricus, acidum phosphoricum aut natrii hydroxidum, chlorocresolum 1 mg, aqua purificata, ad unguentum pro 1 g. - infiammabili, non infetti dermatosi - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - betamethasonum - lozione - betamethasonum 1 mg ut betamethasoni valeras, alcohol cetylicus et stearylicus 10 mg, e 218 1.5 mg, q.s. ad emulsionem pro 1 g. - infiammabili, non infetti dermatosi - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - betamethasonum - salve - betamethasonum 1 mg ut betamethasoni valeras, paraffinum liquidum, vaselinum album, ad unguentum pro 1 g. - infiammabili, non infetti dermatosi - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - betamethasonum, clioquinolum - crema - betamethasonum 1 mg ut betamethasoni valeras, clioquinolum 30 mg, macrogoli aether cetostearylicus, alcohol cetylicus et stearylicus 72 mg, vaselinum album, paraffinum liquidum, natrii dihydrogenophosphas dihydricus, natrii hydroxidum aut acidum phosphoricum, chlorocresolum 1 mg, aqua purificata, ad unguentum pro 1 g. - infiammatoria secondaria infetti dermatosi - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - betamethasonum - soluzione - betamethasonum 1 mg ut betamethasoni valeras, carbomerum 980, alcohol isopropylicus, natrii hydroxidum, aqua purificata, ad solutionem pro 1 g. - infiammabili, non infetti dermatosi del cuoio capelluto - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - salbutamolum - sirup - salbutamolum 2 mg ut salbutamoli sulfas, natrii citras dihydricus, acidum citricum monohydricum, hypromellosum, e 211 10 mg, saccharinum natricum, aromatica (orange), natrii chloridum, aqua purificata, q.s. ad solutionem pro 5 ml, natrium 5.6 mg. - bronchospasmolytikum - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - salbutamolum - soluzione concentrata per aerosolgeräte - salbutamolum 5 mg ut salbutamoli sulfas, benzalkonii chloridum 0.1 mg, acidum sulfuricum, aqua purificata, ad solutionem pro 1 ml. - bronchospasmolytikum - synthetika

Suïssa - italià - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - clobetasoli propionas - crema - unguentum: clobetasoli propionas 0.525 mg, propylenglycolum 475 mg, glyceroli monostearas 40-55, alcohol cetylicus et stearylicus 84 mg, glyceroli monostearas, macrogoli 5000 monostearas, apis cera synthetica, natrii citras dihydricus, acidum citricum monohydricum, chlorocresolum 0.75 mg, aqua purificata, ad unguentum pro 1 g. - non infetto, dermatosi infiammatoria - synthetika